Modular Medical Raises $3.4 Million to Fuel Launch of New Insulin Pump

Modular Medical Raises $3.4 Million to Fuel Launch of New Insulin Pump

2026-04-20 companies

San Diego, Monday, 20 April 2026.
Following recent FDA clearance for its tubeless patch pump, Modular Medical is raising $3.4 million through a discounted share sale to fund its highly anticipated commercial launch.

Structuring the Deal and Immediate Financial Impact

On April 19, 2026, Modular Medical, Inc. (NASDAQ: MODD) announced the pricing of a registered direct offering comprising 750,000 shares of common stock at a price of $4.50 per share [1][2][3][5]. The transaction, brokered by sole placement agent Maxim Group LLC, is expected to generate exact gross proceeds of 3.375 million dollars, equating to roughly $3.4 million before the deduction of agent fees and other offering expenses [1][2][3][5]. Subject to customary closing conditions, the offering is scheduled to close tomorrow, on or about April 21, 2026 [alert! ‘closing dates are subject to change based on customary conditions and regulatory approvals’] [1][2][3][5]. The securities are being issued under a shelf registration statement on Form S-3, which the U.S. Securities and Exchange Commission previously declared effective on May 22, 2025 [1][2][3][5].

Funding the Commercialization of the Pivot Pump

This influx of operating capital arrives at a critical juncture for the San Diego-based medical device developer [4][5]. Modular Medical recently secured U.S. Food and Drug Administration (FDA) 510(k) clearance for its Pivot tubeless insulin patch pump, paving the way for commercial sales within the United States [3][7]. The innovative device features a two-part design that includes a removable 3-milliliter reservoir and a disposable battery, specifically engineered for insulin-dependent adults [7]. The company anticipates initiating product shipments by the end of the second quarter of 2026 [3][7].

Despite technological advancements, Modular Medical has faced substantial financial headwinds. As of mid-April 2026, the company holds a market capitalization of approximately $27.3 million and exhibits a negative return on equity of -3.3 percent [4]. Financial data indicates that the development-stage firm has been rapidly burning through its cash reserves, earning a “WEAK” financial health score from market analysts [3]. Over the past year, the stock price has plummeted by more than 77 percent, reflecting broader market volatility and the inherent capital-intensive nature of medical device commercialization [GPT] [4][7].

Sources


Direct offering Modular Medical